INVION Transforming Photodynamic Therapy: for novel & effective treatments for cancer Invion Limited (ASX: IVX)
INVION IS DEVELOPING PHOTOSOFT™ TECHNOLOGY, THE NEXT-GENERATION PDT Advancing Photosoft™ technology - a novel photosensitiser – with new formulations Lead products of (IVX- P02) for topical and intravenous use IVX-P02 is 15 times more effective in killing cancer cells in in vitro tests against Compelling data ovarian cancer, compared to Photosoft ™ Oral Multiple human clinical trials commencing in Q1, 2019 in Australia and then further Entering the clinic in 2019 global clinical development managed by Invion’s clinical team Clinical development fully funded by The Cho Group, the inventor and owner of Fully funded Photosoft ™ technology Strong track record in taking new drugs from clinical development to regulatory Experienced Board and approval and to market. Rapid progress made since licensing the technology in Management 2018 World-leading SAB and Globally renowned experts in specific cancer fields research Licensed commercial rights for multiple applications across a range of cancers in Diverse portfolio Aus/NZ
How does Photosoft ™ Technology differ from existing PDT treatments: The compound can be activated using multiple wavelengths, allowing for both PHOTOSOFT ™ diagnostic and therapeutic use TECHNOLOGY Water soluble – IVX-P02 compound doesn’t accumulate in the body ADVANTAGES Can be administered via various routes – topical and intravenous. Demonstrates positive immune response in Phase I clinical trials (compared to established PDT treatments that are immunosuppressive)
INVION TEAM : GLOBAL EXPERTS IN CANCER
STRONG EXPERIENCED LEADERSHIP Thian Chew Greg Collier PhD Chairman CEO and Managing Director Managing Partner, Polar Ventures • • 25+yrs experience in clinical drug development, corporate Executive Director, Goldman Sachs proprietary investing (New • management, strategic planning and implementation across York, Hong Kong), public and private across capital structure the global biotechnology industry Director, KPMG Consulting (Singapore, Sydney • • Chairman of Phosphagenics Limited (ASX:POH) Senior Manager, KPMG (Taipei, Melbourne): Audit and assurance, • • Previous: CEO of ChemGenex (sold to Cephalon for $200M+) IT risk management • 150 peer-reviewed publications, 33 patents, Roche Award for Chartered Accountant, MBA/MA Wharton School (Palmer Scholar) • Excellence James Campbell PhD MBA Craig Newton Non-executive Director 20+yrs international experience in scientific research, research • COO management, management consulting and venture capital • 30+ yrs operational experience in Biotech, Medical Devices and big Pharma. CEO of ASX- listed biotechnology company, Patrys Limited • (ASX:PAB) • Previous senior roles at CSL Limited, Serono UK and Australian biotechs. Former CFO & COO at ChemGenex Pharmaceuticals Dr • Campbell has also held research positions at the CNRS and the • Qualified in Medical Science, Management and Marketing CSIRO Alan Yamashita Melanie Farris Non-executive Director CFO & Company Secretary 16-yrs veteran at Goldman Sachs, • Key experience in complex business activities, including • Managing Director & Head of Asian Capital Markets for Merrill Lynch • restructure, IPO, M&A and shareholder action; board President, CEO and CIO of Search Alternative Investment Limited • reporting, board operations and support, financial and (SAIL) compliance reporting Managing Partner, Polar Ventures • Bachelor of Communication (Public Relations), and a • Executive Advisor of Mizuho Alternative Investments • Graduate Diploma in Applied Corporate Governance MPA Princeton, BA Yale • 5
MANAGEMENT TEAM GLOBAL EXPERTS IN DRUG DEVELOPMENT Alexander Bennett Louise White Technical Advisor Manufacturing and Quality Advisor 35+ years experience in senior technical and Over 35 years experience in the pharmaceutical industry • • management at Rofin and at ICI. 13 years experience in a sterile vaccine manufacturing • Product development, QA and international company, CSL and over 22 years within SeerPharma. • commercialisation of light source technology. Louise has held roles in Virology R & D, Bacterial • Physics degree. Vaccines Production, Quality Control and Production • Planning. Louise is a registered auditor for the Australian Pesticides • and Veterinary Manufacturing Authority (APVMA) and current Partner at SeerPharma Dr Sebastian Marcuccio Xenia Sango Chemistry Advisor Regulatory and Clinical Development 15+ years experience in Pharmaceutical and • Over 25 years as a healthcare executive and • organic chemistry developmental research independent consultant 16+ years of commercial experience in smaller • Senior clinical, regulatory and international • scale molecular based companies (Managing commercialisation roles at CSL Limited as Senior Director Director and Founder) of Influenza Commercial Operations; Director of Currently an adjunct Professor at La Trobe • International Registrations, and Head of Regulatory University Affairs. PhD in Organic Chemistry - ANU • Xenia holds a Masters of Science (Chemistry) •
SCIENTIFIC ADVISORS LEADING AUTHORITIES IN CANCER AND PDT Dr Andrew Stephens Assoc. Professor Louis Irving Scientific Advisory Board member Scientific Advisory Board member Lung Cancer; Respiratory Physician, Peter MacCallum 15+ years experience in novel treatment research • • Cancer Centre, and develop • Director, Clinical Training, Royal Melbourne Hospital Founder of the Ovarian Cancer Biomarker Group at • Principal fellowships at the University of Melbourne, in • the Hudson Institute Faculty of Medicine, and Department of Physiology PhD in Biochemistry from Monash and Ovarian • Clinical, teaching and research interests in lung cancer, • Cancer Research Foundation (OCRF) Research advanced bronchoscopy and COPD - has published over Fellow. 100 scientific papers On the Lung Foundation Australia Lung Cancer • Committee, the WCMICS lung cancer group and the Scientific Advisory Committee, National Research Centre for Asbestos Related Diseases. Dr Lynda Spelman Assoc. Professor Nathan Lawrentschuk Scientific Advisory Board member Scientific Advisory Board member 26 years experience in dermatology with special • Urologic Oncologist • interest in clinical research trials Director of Urogology Research Centre, Epworth • conditions, including atopic dermatitis/eczema, • Urological surgeon and oncologist in the Uro-Oncology • chronic plaque psoriasis, palmoplantar psoriasis, Service at the Peter MacCallum Cancer Centre, hidradenitis suppuritiva, seborrheic keratosis, and appointments at The University of Melbourne Department superficial and nodular basal cell carcinoma of Surgery and Olivia Newton-John Institute for Cancer Founder and a director of the Queensland Institute of • Research at the Austin Hospital, Melbourne. Dermatology, Member of the Society of Urologic Oncology (the peak • • Principal Investigator of Veracity Clinical Research North American body for urology cancer surgery) Honorary Secretary of the Queensland Skin and • Cancer Foundation (QSCF) since 2000 Conducted studies in wide range of dermatological •
2018 A YEAR OF RAPID PROGRESS MANUFACTURING- HUDSON RESEARCH SKIN CANCER AGENT COLLOBARATION PROGRAM Contract • IVX-P02 FORMULATION Dr Andrew • Topical formulation • manufacturer Stephens New formulation • for skin cancer engaged appointed to Invion tested in vitro - 15x Industry experts • Process developed • Scientific Advisory more effective than MANUFACTURING – Formulytica for to generate Board Photosoft™ Oral in LIGHT SOURCE formulation & improved drug IVX- ovarian cancer EQUIPMENT Leading research • vivoPharm for pre- P02 institute Data presented at • clinical studies Collaboration • Stable supply • ComBio 2018 with Chinese Multiple projects • manufacturer of underway to LED and laser advance equipment Photosoft TM technology
INVION PDT MECHANISM OF ACTION
ADVANTAGES OF PHOTOSOFT™ TECHNOLOGY Absorbs light in wavelengths to PDT is a proven, effective Is inert without light and “light up” a tumour (diagnostic) or cancer therapy. Photosoft ™ has rapidly clears from cells activate oxygen free radicals that been improved since inception kill cancer cells More effective at killing cancer In vivo tests show that it is Has advantages in wavelength, cells at lower concentrations. Cell selectively taken up by the solubility and selectivity death is not random and is well cancer cells, not normal tissue characterised
PHOTODYNAMIC THERAPY: A NOVEL CANCER TREATMENT Photodynamic therapy (PDT) Combines photosensitiser compound with light-induced activation • Generates reactive oxygen species causing damage to organic molecules • Direct cell death and induction of inflammatory response • Light Necrosis Photosensitiser Cellular Cellular Generation Cell death accumulation Apoptosis localisation damage of reactive via in tumour O 2 tissue Autophagy
Recommend
More recommend